Shearman & Sterling represented BofA Merrill Lynch, Goldman, Sachs & Co., J.P. Morgan, Morgan Stanley and UBS Investment Bank as joint bookrunning managers in connection with Amgen’s registered offering of $3 billion of investment grade notes, consisting of $1.25 billion of 2.125% senior notes due 2017, $750 million of 3.625% senior notes due 2022 and $1 billion of 5.375% senior notes due 2043.
Amgen is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.
The following Shearman & Sterling team advised the underwriters in the transaction: partners John Wilson (San Francisco-Capital Markets), Robert Treuhold (New York-Capital Markets), and James Donato (San Francisco-Litigation); counsel Jung-Kyu McCann (Palo Alto-Capital Markets) andEileen O’Pray (Palo Alto-Tax); and associates Nathan Mee (San Francisco-Capital Markets), Elise Corey (San Francisco-Capital Markets), Daniel Stellenberg (Palo Alto-Executive Compensation & Employee Benefits), Zheng Bao (Palo Alto-Intellectual Property Transactions) and Emily Griffen (San Francisco-Litigation).
Related Posts:
- Shearman & Sterling Advises Initial Purchasers in Broadcom’s $500 Million Offering of Senior Notes
- Shearman & Sterling Advises Managers in Amgen’s Offering of Senior Notes
- Shearman & Sterling Advises on Prospect Medical Holdings, Inc.’s Refinancing Transactions
- Shearman & Sterling Advises on Prospect Medical Holdings, Inc.’s $100 Million Senior Secured Notes Issuance and Consent Solicitation
- Shearman & Sterling Advises on URS Corporation’s $1 Billion Offering of Senior Notes
